CTI BioPharma Statistics
Total Valuation
CCS has a market cap or net worth of $1.71 billion. The enterprise value is $3.21 billion.
| Market Cap | 1.71B |
| Enterprise Value | 3.21B |
Important Dates
The last earnings date was Wednesday, July 23, 2025, after market close.
| Earnings Date | Jul 23, 2025 |
| Ex-Dividend Date | May 28, 2025 |
Share Statistics
CCS has 29.68 million shares outstanding. The number of shares has decreased by -2.23% in one year.
| Current Share Class | 29.68M |
| Shares Outstanding | 29.68M |
| Shares Change (YoY) | -2.23% |
| Shares Change (QoQ) | -1.49% |
| Owned by Insiders (%) | 15.36% |
| Owned by Institutions (%) | 95.08% |
| Float | 25.11M |
Valuation Ratios
The trailing PE ratio is 6.98 and the forward PE ratio is 9.71.
| PE Ratio | 6.98 |
| Forward PE | 9.71 |
| PS Ratio | 0.41 |
| Forward PS | 0.37 |
| PB Ratio | 0.67 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | 36.43 |
| P/OCF Ratio | 10.94 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.52, with an EV/FCF ratio of 68.19.
| EV / Earnings | 12.33 |
| EV / Sales | 0.74 |
| EV / EBITDA | 8.52 |
| EV / EBIT | 9.15 |
| EV / FCF | 68.19 |
Financial Position
The company has a current ratio of 5.37, with a Debt / Equity ratio of 0.62.
| Current Ratio | 5.37 |
| Quick Ratio | 0.21 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 4.14 |
| Debt / FCF | 33.75 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 10.34% and return on invested capital (ROIC) is 5.44%.
| Return on Equity (ROE) | 10.34% |
| Return on Assets (ROA) | 4.91% |
| Return on Invested Capital (ROIC) | 5.44% |
| Return on Capital Employed (ROCE) | 9.16% |
| Revenue Per Employee | $2.30M |
| Profits Per Employee | $138,814 |
| Employee Count | 1,873 |
| Asset Turnover | 0.97 |
| Inventory Turnover | 0.99 |
Taxes
In the past 12 months, CCS has paid $84.71 million in taxes.
| Income Tax | 84.71M |
| Effective Tax Rate | 24.57% |
Stock Price Statistics
The stock price has decreased by -44.89% in the last 52 weeks. The beta is 1.40, so CCS's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -44.89% |
| 50-Day Moving Average | 56.49 |
| 200-Day Moving Average | 70.02 |
| Relative Strength Index (RSI) | 47.66 |
| Average Volume (20 Days) | 403,696 |
Short Selling Information
The latest short interest is 1.91 million, so 6.44% of the outstanding shares have been sold short.
| Short Interest | 1.91M |
| Short Previous Month | 2.01M |
| Short % of Shares Out | 6.44% |
| Short % of Float | 7.61% |
| Short Ratio (days to cover) | 4.46 |
Income Statement
In the last 12 months, CCS had revenue of $4.31 billion and earned $260.00 million in profits. Earnings per share was $8.26.
| Revenue | 4.31B |
| Gross Profit | 876.30M |
| Operating Income | 350.30M |
| Pretax Income | 433.03M |
| Net Income | 260.00M |
| EBITDA | 376.28M |
| EBIT | 350.30M |
| Earnings Per Share (EPS) | $8.26 |
Balance Sheet
The company has $93.25 million in cash and $1.59 billion in debt, giving a net cash position of -$1.49 billion or -$50.32 per share.
| Cash & Cash Equivalents | 93.25M |
| Total Debt | 1.59B |
| Net Cash | -1.49B |
| Net Cash Per Share | -$50.32 |
| Equity (Book Value) | 2.56B |
| Book Value Per Share | 86.39 |
| Working Capital | 3.31B |
Cash Flow
In the last 12 months, operating cash flow was $156.53 million and capital expenditures -$109.51 million, giving a free cash flow of $47.02 million.
| Operating Cash Flow | 156.53M |
| Capital Expenditures | -109.51M |
| Free Cash Flow | 47.02M |
| FCF Per Share | $1.58 |
Margins
Gross margin is 20.31%, with operating and profit margins of 8.12% and 6.03%.
| Gross Margin | 20.31% |
| Operating Margin | 8.12% |
| Pretax Margin | 7.99% |
| Profit Margin | 6.03% |
| EBITDA Margin | 8.72% |
| EBIT Margin | 8.12% |
| FCF Margin | 1.09% |
Dividends & Yields
This stock pays an annual dividend of $1.16, which amounts to a dividend yield of 2.06%.
| Dividend Per Share | $1.16 |
| Dividend Yield | 2.06% |
| Dividend Growth (YoY) | 12.24% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 13.31% |
| Buyback Yield | 2.23% |
| Shareholder Yield | 4.24% |
| Earnings Yield | 15.18% |
| FCF Yield | 2.75% |
Analyst Forecast
The average price target for CCS is $80.75, which is 39.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $80.75 |
| Price Target Difference | 39.92% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CCS has an Altman Z-Score of 3.45 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.45 |
| Piotroski F-Score | 3 |